Article | November 18, 2020

Optimize Scale-Up And Increase Capacity For Vaccine And Therapeutic Manufacturing

By Robert Hendrix, Staff Engineer, Systems Design, Single-Use Technologies; Kathryn Barnes, Process Improvement Manager, Production Chemicals and Services; Joe Gallo, Associate Product Manager, Production Chemicals and Services; Julie Bray, Production Support Services Senior Manager, Pharma Services; Adam Goldstein, Sr. Director, Research and Development Collaborations, Single-Use Technologies; Thermo Fisher Scientific

Thermo Fisher

Accelerate development and manufacturing in the era of SARS-CoV-2

To meet the urgent demand for SARS-CoV-2 vaccines and therapeutics in the shortest possible timeframe, many companies are designing their scale-up processes in parallel with Phase III clinical trials, redefining the risk tolerance for everyone involved. To satisfy commercial requirements for expedited scale-up, the molecule can no longer dictate the technology transfer process into the manufacturing facility.

Shifting the focus from optimizing an individual process to an entire biomanufacturing workflow requires companies to adopt a new mindset and consider new ways of doing business. Success can be achieved by concentrating on three key activities: reviewing capabilities, assessing your risk tolerance, and identifying additional resources to accomplish your goals.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online